Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Orlucent, Inc
Eastern Cooperative Oncology Group
Protara Therapeutics
Protara Therapeutics
Institut Claudius Regaud
CG Oncology, Inc.
Bayer
University of Pittsburgh
Hiantis Srl
Medical University of Vienna
Medical University of Vienna
University of Arizona
M.D. Anderson Cancer Center
Bayer
Rigshospitalet, Denmark
National Institutes of Health Clinical Center (CC)
University Hospital Ostrava
McGill University
Anandasabapathy, Sharmila, M.D.
Ohio State University
Endo Pharmaceuticals
The HIV Netherlands Australia Thailand Research Collaboration
Telormedix SA
Materno-Perinatal Hospital of the State of Mexico
Spectrum Pharmaceuticals, Inc
Johannes Gutenberg University Mainz